Plasma Soluble Glycoprotein VI: A Biomarker of Bleeding

Note

David J. Schneider is the named inventor on a patent (Patent No.: 10,502,737) that proposes the use of FcγRIIa for assaying platelet reactivity and treatment selection.

Publication History

Received: 21 August 2023

Accepted: 23 August 2023

Accepted Manuscript online:
24 August 2023

Article published online:
18 September 2023

• References

• 1 Lahu S, Adler K, Mayer K. et al. Plasma soluble glycoprotein VI, platelet function, bleeding, and ischemic events in patients undergoing elective percutaneous coronary intervention. Thromb Haemost 2024; 124 (04) 297-306
• 2 Al-Tamimi M, Arthur JF, Gardiner E, Andrews RK. Focusing on plasma glycoprotein VI. Thromb Haemost 2012; 107 (04) 648-655
• 3 Pishko AM, Andrews RK, Gardiner EE, Lefler DS, Cuker A. Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia. Blood Adv 2020; 4 (18) 4327-4332
• 4 Muthiah K, Connor D, Ly K. et al. Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices. J Heart Lung Transplant 2016; 35 (06) 743-751
• 5 Chen Z, Zhang J, Kareem K. et al. Device-induced platelet dysfunction in mechanically assisted circulation increases the risks of thrombosis and bleeding. Artif Organs 2019; 43 (08) 745-755
• 6 Hijazi Z, Oldgren J, Lindbäck J. et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
• 7 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010; 138: 1093-1100
• 8 O'Brien EC, Simon DN, Thomas LE. et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36 (46) 3258-3264
• 9 Zhang S, Hao P, Li J. et al. Prognostic value of growth differentiation factor-15 in patients with coronary artery disease: a meta-analysis and systematic review. Front Cardiovasc Med 2023; 10: 1054187
• 10 Zhou Z, Liu H, Ju H, Chen H, Jin H, Sun M. Circulating GDF-15 in relation to the progression and prognosis of chronic kidney disease: a systematic review and dose-response meta-analysis. Eur J Intern Med 2023; 110: 77-85
• 11 Xie S, Li Q, Luk AOY. et al. Major adverse cardiovascular events and mortality prediction by circulating GDF-15 in patients with type 2 diabetes: a systematic review and meta-analysis. Biomolecules 2022; 12 (07) 934
• 12 Xie S, Lu L, Liu L. Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: a meta-analysis of prospective studies. Clin Cardiol 2019; 42 (05) 513-523
• 13 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-Stroke and ABC-Bleeding Scores in patients with atrial fibrillation: the Murcia AF Project. Thromb Haemost 2020; 120 (08) 1200-1207
• 14 Myhre PL, Prebensen C, Strand H. et al. Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19. Circulation 2020; 142 (22) 2128-2137
• 15 López-Gálvez R, Rivera-Caravaca JM. Growth differentiation factor 15 in cardiovascular diseases: predicting bleeding after cardiac surgery and beyond that!. Thromb Haemost 2022; 122 (05) 657-660
• 16 Aota T, Naitoh K, Wada H. et al. Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. Int J Hematol 2014; 100 (05) 450-456
• 17 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-pacific expert consensus paper. Thromb Haemost 2022; 122 (10) 1625-1652
• 18 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
• 19 Hsieh MJ, Lee CH, Chen CC, Chang SH, Wang CY, Hsieh IC. Predictive performance of HAS-BLED risk score for long-term survival in patients with non-ST elevated myocardial infarction without atrial fibrillation. J Cardiol 2017; 69 (01) 136-143
• 20 Shimono H, Tokushige A, Kanda D. et al. Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome. J Cardiol 2023; 81 (06) 553-563
• 21 Pasea L, Chung SC, Pujades-Rodriguez M. et al. Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. BMC Med 2019; 17 (01) 206
• 22 Kaikita K, Yasuda S, Akao M. et al. Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial. Circ Cardiovasc Interv 2021; 14 (11) e010476